Anesthetic management of patients receiving calculus therapy with a third-generation extracorporeal lithotripsy machine

Michael Hosking, Steve A. Morris, Frederick A. Klein, Cindy Dobmeyer-Dittrich

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We reviewed the anesthetic requirements for satisfactory use of a third-generation electromagnetic-source design for extracorporeal shockwave lithotripsy (SWL). Medical records were reviewed for a period of 9 months on all patients receiving anesthesia care for SWL with and without other urologic procedures. The Modulith® SL20 was used on 56 ASA Class I-III patients having 87 SWL treatments. Demographic and anesthetic variables were recorded. Complications documented included dysrhythmias, nausea necessitating treatment, and conversion from sedation to regional or general anesthesia. The majority of procedures (83%) were performed on an outpatient basis. Patients were classified as ASA physical status I (27%), II (63%), or III (10%). Monitored anesthesia care with intravenous sedation was utilized in 93% of cases. Of these cases, 78 involved a combination of intravenous propofol, fentanyl, and midazolam; the remaining 3 involved propofol, alfentanil, and/or midazolam. The mean treatment duration was 36 minutes. Patients were discharged within 1 hour after procedure completion in 77 cases (89%). Nausea necessitating treatment was rare (3%). The mean dose of propofol administered with SWL as the only procedure was 272 ± 112 mg. When SWL was combined with other urologic procedures, the mean dose of propofol was 334 ± 121 mg. Continuous intravenous propofol infusion provides excellent procedural conditions for SWL on the Modulith® SL120, a third-generation lithotripter.

Original languageEnglish (US)
Pages (from-to)309-311
Number of pages3
JournalJournal of Endourology
Volume11
Issue number5
DOIs
StatePublished - Jan 1 1997
Externally publishedYes

Fingerprint

Lithotripsy
Calculi
Propofol
Anesthetics
Midazolam
Nausea
Therapeutics
Anesthesia
Alfentanil
Conduction Anesthesia
Electromagnetic Phenomena
Fentanyl
Intravenous Infusions
General Anesthesia
Medical Records
Outpatients
Demography

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Anesthetic management of patients receiving calculus therapy with a third-generation extracorporeal lithotripsy machine. / Hosking, Michael; Morris, Steve A.; Klein, Frederick A.; Dobmeyer-Dittrich, Cindy.

In: Journal of Endourology, Vol. 11, No. 5, 01.01.1997, p. 309-311.

Research output: Contribution to journalArticle

Hosking, Michael ; Morris, Steve A. ; Klein, Frederick A. ; Dobmeyer-Dittrich, Cindy. / Anesthetic management of patients receiving calculus therapy with a third-generation extracorporeal lithotripsy machine. In: Journal of Endourology. 1997 ; Vol. 11, No. 5. pp. 309-311.
@article{b9910197e36e47c986d44ada46870beb,
title = "Anesthetic management of patients receiving calculus therapy with a third-generation extracorporeal lithotripsy machine",
abstract = "We reviewed the anesthetic requirements for satisfactory use of a third-generation electromagnetic-source design for extracorporeal shockwave lithotripsy (SWL). Medical records were reviewed for a period of 9 months on all patients receiving anesthesia care for SWL with and without other urologic procedures. The Modulith{\circledR} SL20 was used on 56 ASA Class I-III patients having 87 SWL treatments. Demographic and anesthetic variables were recorded. Complications documented included dysrhythmias, nausea necessitating treatment, and conversion from sedation to regional or general anesthesia. The majority of procedures (83{\%}) were performed on an outpatient basis. Patients were classified as ASA physical status I (27{\%}), II (63{\%}), or III (10{\%}). Monitored anesthesia care with intravenous sedation was utilized in 93{\%} of cases. Of these cases, 78 involved a combination of intravenous propofol, fentanyl, and midazolam; the remaining 3 involved propofol, alfentanil, and/or midazolam. The mean treatment duration was 36 minutes. Patients were discharged within 1 hour after procedure completion in 77 cases (89{\%}). Nausea necessitating treatment was rare (3{\%}). The mean dose of propofol administered with SWL as the only procedure was 272 ± 112 mg. When SWL was combined with other urologic procedures, the mean dose of propofol was 334 ± 121 mg. Continuous intravenous propofol infusion provides excellent procedural conditions for SWL on the Modulith{\circledR} SL120, a third-generation lithotripter.",
author = "Michael Hosking and Morris, {Steve A.} and Klein, {Frederick A.} and Cindy Dobmeyer-Dittrich",
year = "1997",
month = "1",
day = "1",
doi = "10.1089/end.1997.11.309",
language = "English (US)",
volume = "11",
pages = "309--311",
journal = "Journal of Endourology",
issn = "0892-7790",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Anesthetic management of patients receiving calculus therapy with a third-generation extracorporeal lithotripsy machine

AU - Hosking, Michael

AU - Morris, Steve A.

AU - Klein, Frederick A.

AU - Dobmeyer-Dittrich, Cindy

PY - 1997/1/1

Y1 - 1997/1/1

N2 - We reviewed the anesthetic requirements for satisfactory use of a third-generation electromagnetic-source design for extracorporeal shockwave lithotripsy (SWL). Medical records were reviewed for a period of 9 months on all patients receiving anesthesia care for SWL with and without other urologic procedures. The Modulith® SL20 was used on 56 ASA Class I-III patients having 87 SWL treatments. Demographic and anesthetic variables were recorded. Complications documented included dysrhythmias, nausea necessitating treatment, and conversion from sedation to regional or general anesthesia. The majority of procedures (83%) were performed on an outpatient basis. Patients were classified as ASA physical status I (27%), II (63%), or III (10%). Monitored anesthesia care with intravenous sedation was utilized in 93% of cases. Of these cases, 78 involved a combination of intravenous propofol, fentanyl, and midazolam; the remaining 3 involved propofol, alfentanil, and/or midazolam. The mean treatment duration was 36 minutes. Patients were discharged within 1 hour after procedure completion in 77 cases (89%). Nausea necessitating treatment was rare (3%). The mean dose of propofol administered with SWL as the only procedure was 272 ± 112 mg. When SWL was combined with other urologic procedures, the mean dose of propofol was 334 ± 121 mg. Continuous intravenous propofol infusion provides excellent procedural conditions for SWL on the Modulith® SL120, a third-generation lithotripter.

AB - We reviewed the anesthetic requirements for satisfactory use of a third-generation electromagnetic-source design for extracorporeal shockwave lithotripsy (SWL). Medical records were reviewed for a period of 9 months on all patients receiving anesthesia care for SWL with and without other urologic procedures. The Modulith® SL20 was used on 56 ASA Class I-III patients having 87 SWL treatments. Demographic and anesthetic variables were recorded. Complications documented included dysrhythmias, nausea necessitating treatment, and conversion from sedation to regional or general anesthesia. The majority of procedures (83%) were performed on an outpatient basis. Patients were classified as ASA physical status I (27%), II (63%), or III (10%). Monitored anesthesia care with intravenous sedation was utilized in 93% of cases. Of these cases, 78 involved a combination of intravenous propofol, fentanyl, and midazolam; the remaining 3 involved propofol, alfentanil, and/or midazolam. The mean treatment duration was 36 minutes. Patients were discharged within 1 hour after procedure completion in 77 cases (89%). Nausea necessitating treatment was rare (3%). The mean dose of propofol administered with SWL as the only procedure was 272 ± 112 mg. When SWL was combined with other urologic procedures, the mean dose of propofol was 334 ± 121 mg. Continuous intravenous propofol infusion provides excellent procedural conditions for SWL on the Modulith® SL120, a third-generation lithotripter.

UR - http://www.scopus.com/inward/record.url?scp=0031424627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031424627&partnerID=8YFLogxK

U2 - 10.1089/end.1997.11.309

DO - 10.1089/end.1997.11.309

M3 - Article

VL - 11

SP - 309

EP - 311

JO - Journal of Endourology

JF - Journal of Endourology

SN - 0892-7790

IS - 5

ER -